Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

Published on: 04.03.2019

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC. 

‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’

Topics that are discussed in this e-learning are:

  • When are we ready for adjuvant therapy?
  • What is the role of cytoreductive nephrectomy in mRCC?
  • How to choose from the available options for first, second, and third line treatment?
  • What may be the impact of immunotherapy and novel TKIs on the treatment algorithm?

Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

  • Sponsors

    This program is editorially independent and is financially supported by: